The Case CCC Radiation Resources Core Facility (RRCF) provides an essential service to the Cancer Center, since ionizing radiation has both carcinogenic and therapeutic roles in cancer and can produce viable, but non-reproductive cells for a variety of other studies. The Facility serves two types of cancer researchers: those studying the cancer-causing and cancer-treating actions of radiation, and those with primary interests in other topics for whom radiation is an essential tool, e.g., for killing cells to prepare feeder layers for growth of embryonic stem cells, or to study the immunogenic properties of cancer cells. The objectives of the RRCF are: 1) To maintain and operate ionizing radiation-producing devices for cancer researchers; 2) To consult with users concerning the instrumentation, the services, the training requirements, and if desired, the experimental design; 3) To train new users in proper operation of the equipment;and; 4) To provide support for implementation of new security regulations. The Radiation Resources Core supports researchers from 7 of the 8 Scientific Research Programs, with the heaviest use by the Hematopoietic Disorders Program. The RRCF supports research concerning the effects of radiation in which the interest is to determine the mechanism of its action or to improve radiation therapeutics. The facility also provides extensive services for those with other interests in cancer research, but for whom radiation is necessary for the construction of feeder layers, the ablation of the immune response of animals, or the sterilization of reagents, as exemplified by published studies of several other cancer researchers. For both categories of Cancer Center researchers, the RRCF is an essential resource without which their research could not be accomplished.
The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.
|Levinson, Kimberly L; Jernigan, Amelia M; Flocke, Susan A et al. (2016) Intimate Partner Violence and Barriers to Cervical Cancer Screening: A Gynecologic Oncology Fellow Research Network Study. J Low Genit Tract Dis 20:47-51|
|Cooper, Gregory S; Kou, Tzuyung D; Schluchter, Mark D et al. (2016) Changes in Receipt of Cancer Screening in Medicare Beneficiaries Following the Affordable Care Act. J Natl Cancer Inst 108:|
|Wiechert, Andrew; Saygin, Caner; Thiagarajan, Praveena S et al. (2016) Cisplatin induces stemness in ovarian cancer. Oncotarget 7:30511-22|
|Somasegar, Sahana; Li, Li; Thompson, Cheryl L (2016) No association of reproductive risk factors with breast cancer tumor grade. Eur J Cancer Prev :|
|Kenyon, Jonathan; Nickel-Meester, Gabrielle; Qing, Yulan et al. (2016) Epigenetic Loss of MLH1 Expression in Normal Human Hematopoietic Stem Cell Clones is Defined by the Promoter CpG Methylation Pattern Observed by High-Throughput Methylation Specific Sequencing. Int J Stem Cell Res Ther 3:|
|Dowlati, A; Lipka, M B; McColl, K et al. (2016) Clinical correlation of extensive-stage small-cell lung cancer genomics. Ann Oncol 27:642-7|
|Markowitz, Sanford D; Nock, Nora L; Schmit, Stephanie L et al. (2016) A Germline Variant on Chromosome 4q31.1 Associates with Susceptibility to Developing Colon Cancer Metastasis. PLoS One 11:e0146435|
|Wang, Y; Deng, O; Feng, Z et al. (2016) RNF126 promotes homologous recombination via regulation of E2F1-mediated BRCA1 expression. Oncogene 35:1363-72|
|Doherty, Mary R; Smigiel, Jacob M; Junk, Damian J et al. (2016) Cancer Stem Cell Plasticity Drives Therapeutic Resistance. Cancers (Basel) 8:|
|Blum, Andrew E; Venkitachalam, Srividya; Guo, Yan et al. (2016) RNA Sequencing Identifies Transcriptionally Viable Gene Fusions in Esophageal Adenocarcinomas. Cancer Res 76:5628-5633|
Showing the most recent 10 out of 1148 publications